guttitude logo

guttitude

early access
Get Checklistguttitude Pro
← Back to atlas
fulltoplow inflation risk

Bacteroides vulgatus

type 2 diabetes

Bacteroides vulgatus looks like a credible signal in type 2 diabetes, though some caution is still warranted.

Bacteroides vulgatus shows a strong literature footprint in type 2 diabetes, with substantial central evidence and broader supporting literature.

bacteroides_vulgatus
Credibility score
68
Human translation
3/5
Reproducibility
4/5
Novelty
2/5
Actionability
5/5
Credibility 68Human translation 3/5Reproducibility 4/5Novelty 2/5Actionability 5/5
Why this scores the way it does
  • strong central evidence base
  • meaningful supporting human literature
  • substantial preclinical support
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

20 papers
Detection of Increased Plasma Interleukin-6 Levels and Prevalence of Prevotella copri and Bacteroides vulgatus in the Feces of Type 2 Diabetes Patients.
2017
Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.
2019
Cell death & disease
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India.
2021
Genome medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characteristics of the gut microbiome in patients with prediabetes and type 2 diabetes.
2021
PeerJ
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metagenomic analysis revealed the potential role of gut microbiome in gout.
2021
NPJ biofilms and microbiomes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characterization of Gut Microbiota Composition in Type 2 Diabetes Patients: A Population-Based Study.
2022
International journal of environmental research and public health
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiome Features Differentiating Unsupervised-Stratification-Based Clusters of Patients with Abnormal Glycometabolism.
2023
mBio
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method.
2023
Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the Gut Microbiota in Pregnant Women with Pregestational Type 2 Diabetes Mellitus.
2023
mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Jiang-Tang-San-Huang pill alleviates type 2 diabetes mellitus through modulating the gut microbiota and bile acids metabolism.
2023
Phytomedicine : international journal of phytotherapy and phytopharmacology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Changes in the Microbiota and their Roles in Patients with Type 2 Diabetes Mellitus.
2023
Current microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the gut virome are associated with type 2 diabetes and diabetic nephropathy.
2023
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiome profile of Chinese hypertension patients with and without type 2 diabetes mellitus.
2023
BMC microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Role of Gut Microbiota in Statin-Associated New-Onset Diabetes-A Cross-Sectional and Prospective Analysis of the FINRISK 2002 Cohort.
2024
Arteriosclerosis, thrombosis, and vascular biology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Functional alterations and predictive capacity of gut microbiome in type 2 diabetes.
2023
Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A study on the association between gut microbiota, inflammation, and type 2 diabetes.
2024
Applied microbiology and biotechnology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mapping multi-omics characteristics related to short-term PM2.5 trajectory and their impact on type 2 diabetes in middle-aged and elderly adults in Southern China.
2024
Journal of hazardous materials
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Quantification and Correlation Analysis of Bacteroides Species with Diabetes-Related Amino Acids in Individuals with Prediabetes and Type 2 Diabetes Mellitus.
2024
Metabolic syndrome and related disorders
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota composition and type 2 diabetes: Are these subjects linked Together?
2024
Heliyon
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal Microbiota Composition in Patients with Type 2 Diabetes and Effects of Oral Antidiabetics.
2025
Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Supporting primary evidence

2 papers
Akkermansia muciniphila is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes.
2020
Microorganisms
Human primary paper with plausible association relevance to the disease context.
Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.
2025
Gut microbes
Human primary paper with plausible association relevance to the disease context.

Preclinical supporting evidence

18 papers
Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.
2008
Diabetes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human gut microbes impact host serum metabolome and insulin sensitivity.
2016
Nature
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.
2018
Nature medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology.
2020
Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Characterisation of gut microbiota of obesity and type 2 diabetes in a rodent model.
2021
Bioscience of microbiota, food and health
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut dysbiosis, inflammation and type 2 diabetes in mice using synthetic gut microbiota from diabetic humans.
2021
Brazilian journal of biology = Revista brasleira de biologia
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease.
2021
Computational and structural biotechnology journal
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Shenqi compound ameliorates type-2 diabetes mellitus by modulating the gut microbiota and metabolites.
2022
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The human gut microbiota contributes to type-2 diabetes non-resolution 5-years after Roux-en-Y gastric bypass.
2022
Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Snapshot into the Type-2-Diabetes-Associated Microbiome of a Romanian Cohort.
2022
International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Glycoursodeoxycholic acid regulates bile acids level and alters gut microbiota and glycolipid metabolism to attenuate diabetes.
2023
Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacteroides ovatus accelerates metformin-induced vitamin B12 deficiency in type 2 diabetes patients by accumulating cobalamin.
2023
NPJ biofilms and microbiomes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus.
2023
Frontiers in endocrinology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.
2024
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The inflammatory bowel disease and gut microbiome are restored by employing metformin-loaded alginate-shelled microcapsules.
2025
Journal of controlled release : official journal of the Controlled Release Society
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial.
2025
Nature microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dasatinib and Quercetin alleviate type 2 diabetic osteoporosis by regulating serum metabolite and gut microbiome.
2025
Frontiers in microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
An endoscopic real-time, in situ assessment of intestinal permeability in type 2 diabetes: links to microbiota and hyperglycemia.
2026
Journal of gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

9 papers
Role of gut microbiota in type 2 diabetes pathophysiology.
2020
EBioMedicine
Relevant review or meta-analysis for the signal-disease area.
Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus.
2020
Diabetes, metabolic syndrome and obesity : targets and therapy
Relevant review or meta-analysis for the signal-disease area.
Human microbiome and metabolic health: An overview of systematic reviews.
2022
Obesity reviews : an official journal of the International Association for the Study of Obesity
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and physical exercise in obesity and diabetes - A systematic review.
2022
Nutrition, metabolism, and cardiovascular diseases : NMCD
Relevant review or meta-analysis for the signal-disease area.
Intestinal phages interact with bacteria and are involved in human diseases.
2022
Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review.
2023
Genes
Relevant review or meta-analysis for the signal-disease area.
Type-2 Diabetes Mellitus and the Gut Microbiota: Systematic Review.
2023
Cureus
Relevant review or meta-analysis for the signal-disease area.
Polysaccharides in Medicinal and Food Homologous Plants regulate intestinal flora to improve type 2 diabetes: Systematic review.
2024
Phytomedicine : international journal of phytotherapy and phytopharmacology
Relevant review or meta-analysis for the signal-disease area.
A systematic review on gut microbiota in type 2 diabetes mellitus.
2024
Frontiers in endocrinology
Relevant review or meta-analysis for the signal-disease area.